Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

This enzyme is key to DNA repair in cells, so blocking it leads to cell death. Though PARP inhibitors are already approved to treat certain cancers, they come with toxicity risks thought to be ...

Figure 2: Classification of the poly-ADP-ribose-polymerase (PARP) family according to the structural model proposed by Kleine et al.7. To identify the PARP10 residues that are post-translationally ...

A day of celebration that Forestville Elementary School has fostered for more than four decades was held last month. The ...

Eisbach Bio plans to use a $4.75m grant to advance EIS-12656, a small molecule ALC1 inhibitor to disrupt the genome structure in hard-to-treat cancer cells, says CEO Dr. Adrian Schomburg.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers. It has ...

Therapeutics announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating ...

Opens in a new tab or window An analysis of a phase III trial presented at this year's American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium showed that adding the PARP ...